A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40

Jingtao Chen, Gerard Zurawski, Sandy Zurawski, Zhiqing Wang, Keiko Akagawa, Sangkon Oh, Ueno Hideki, Joseph Fay, Jacques Banchereau, Wenru Song, A. Karolina Palucka

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy. Methods: We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40. Results: Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Conclusions: This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.

Original languageEnglish (US)
Article number35
JournalJournal of Hematology and Oncology
Volume8
Issue number1
DOIs
StatePublished - Apr 14 2015

Keywords

  • Cyclin D1
  • Dendritic cells
  • Mantle cell lymphoma
  • Tumor antigen
  • Vaccine

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40'. Together they form a unique fingerprint.

Cite this